Some US Food and Drug Administration staff continue to struggle with remote inspections as stakeholders press for greater use of the pandemic work-around to reduce a growing backlog of facilities waiting for the visits.
Lawmakers wondered during a House Energy and Commerce Health Subcommittee hearing earlier this month how alternative inspection tools can be used more effectively, including for generic and biosimilar facilities